Skip to main content
. 2021 Jul 28;2021(7):CD015017. doi: 10.1002/14651858.CD015017.pub2

2.1. Analysis.

2.1

Comparison 2: Ivermectin compared to placebo or standard of care for people with mild COVID‐19 treated in the outpatient setting, Outcome 1: All‐cause mortality up to 28 days (primary analysis)